MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells

Cell Death and Differentiation

Volumn 23, Issue 2, 2016, Pages 242-252

  Knackmuss, U ^a,b   Lindner, S E ^b   Aneichyk, T ^b   Kotkamp, B ^a   Knust, Z ^a   Villunger, A ^b   Herzog, S ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 125B; MITOGEN ACTIVATED PROTEIN KINASE; MICRORNA; MIRN125 MICRORNA, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ANIMAL; B CELL LEUKEMIA; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; ENZYME REPRESSION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; LEUKEMIA; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ENZYME REPRESSION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA; LEUKEMIA, B-CELL; MAP KINASE KINASE KINASES; MICE; MICE, KNOCKOUT; MICRORNAS; NEOPLASM TRANSPLANTATION; PRECURSOR CELLS, B-LYMPHOID; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84954371543     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.87     Document Type: Article

References (55)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
2. Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009; 136: 26-36.
3. Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 2008; 132: 860-874.
4. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355.
5. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26: 2011-2018.
6. O'Connell RMR, Chaudhuri AAA, Rao DSD, Gibson WSJW, Balazs ABA, Baltimore DD. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA 2010; 107: 14235-14240.
7. Ooi AGL, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA 2010; 107: 21505-21510.
8. Chaudhuri AA, So AY-L, Mehta A, Minisandram A, Sinha N, Jonsson VD et al. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA 2012; 109: 4233-4238.
9. Gururajan M, Haga CL, Das S, Leu C-M, Hodson D, Josson S et al. MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int Immunol 2010; 22: 583-592.
10. Rossi RL, Rossetti G, Wenandy L, Curti S, Ripamonti A, Bonnal RJP et al. Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol 2011; 12: 796-803.
11. Chaudhuri AA, So AY-L, Sinha N, Gibson WSJ, Taganov KD, O'Connell RM et al. MicroRNA-125b potentiates macrophage activation. J Immunol 2011; 187: 5062-5068.
12. Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011; 25: 1849-1856.
13. Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia 2009; 24: 89-96.
14. Sonoki T, Iwanaga E, Mitsuya H, Asou N. Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia 2005; 19: 2009-2010.
15. Chapiro E, Russell LJ, Struski S, Cavé H, Radford-Weiss I, Valle VD et al. A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia 2010; 24: 1362-1364.
16. Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C. MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukemia. Genes Chromosome Cancer 2010; 49: 682-687.
17. Zhang H, Luo X-Q, Feng D-D, Zhang X-J, Wu J, Zheng Y-S et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011; 10: 108.
18. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114: e20-e26.
19. Klusmann JH, Li Z, Böhmer K, Maroz A, Koch ML, Emmrich S et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010; 24: 478-490.
20. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008; 205: 2499-2506.
21. Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA 2010; 107: 21558-21563.
22. Shi X-B, Xue L, Yang J, Ma A-H, Zhao J, Xu M et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983-19988.
23. So AY-L, Sookram R, Chaudhuri AA, Minisandram A, Cheng D, Xie C et al. Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid and B cell leukemias. Blood 2014; 124: 1502-1512.
24. Bousquet M, Nguyen D, Chen C, Shields L, Lodish HF. MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA. Haematologica 2012; 97: 1713-17121.
25. Kim S-W, Ramasamy K, Bouamar H, Lin A-P, Jiang D, Aguiar RCT. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 2012; 109: 7865-78670.
26. Puissegur MP, Eichner R, Quelen C, Coyaud E, Mari B, Lebrigand K et al. B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. Leukemia 2012; 26: 2224-2232.
27. Su Y-W, Jumaa H. LAT links the pre-BCR to calcium signaling. Immunity 2003; 19: 295-305.
28. Kuchen S, Resch W, Yamane A, Kuo N, Li Z, Chakraborty T et al. Regulation of microRNA expression and abundance during lymphopoiesis. Immunity 2010; 32: 828-839.
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
30. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
31. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39: 1278-1284.
32. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-D153.
33. Eekels JJM, Pasternak AO, Schut AM, Geerts D, Jeeninga RE, Berkhout B. A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation. Gene Therapy 2012; 19: 1058-1064.
34. Hartkamp J, Troppmair J, Rapp UR. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res 1999; 59: 2195-2202.
35. Chadee DN, Kyriakis JM. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat Cell Biol 2004; 6: 770-776.
36. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
37. Guo S, Bai H, Megyola CM, Halene S, Krause DS, Scadden DT et al. Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. Proc Natl Acad Sci USA 2012; 109: 16636-16641.
38. Surdziel E, Cabanski M, Dallmann I, Lyszkiewicz M, Krueger A, Ganser A et al. Enforced expression of miR-125b affects myelopoiesis by targeting multiple signaling pathways. Blood 2011; 117: 4338-4348.
39. Amir S, Ma A-H, Shi X-B, Xue L, Kung H-J, de Vere White RW. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One 2013; 8: e61064.
40. Le MTN, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet 2011; 7: e1002242.
41. Brancho D, Ventura J-J, Jaeschke A, Doran B, Flavell RA, Davis RJ. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol Cell Biol 2005; 25: 3670-3681.
42. Zhang Y, Yan L-X, Wu Q-N, Du Z-M, Chen J, Liao D-Z et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011; 71: 3552-3562.
43. Chen J, Miller EM, Gallo KA. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 2010; 29: 4399-4411.
44. Zhang J, Lu L, Xiong Y, Qin W, Zhang Y, Qian Y et al. MLK3 promotes melanoma proliferation and invasion and is a target of microRNA-125b. Clin Exp Dermatol 2014; 39: 376-384.
45. Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 2007; 26: 323-333.
46. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-1066.
47. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nat Cell Biol 2005; 435: 828-833.
48. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289-1295.
49. Strack RL, Strongin DE, Bhattacharyya D, Tao W, Berman A, Broxmeyer HE et al. A noncytotoxic DsRed variant for whole-cell labeling. Nat Methods 2008; 5: 955-957.
50. Herzog S, Jumaa H. The N terminus of the non-T cell activation linker (NTAL) confers inhibitory effects on pre-B cell differentiation. J Immunol 2007; 178: 2336-2343.
51. Danke C, Grünz X, Wittmann J, Schmidt A, Agha-Mohammadi S, Kutsch O et al. Adjusting transgene expression levels in lymphocytes with a set of inducible promoters. J Gene Med 2010; 12: 501-515.
52. Qiu L, Wang H, Xia X, Zhou H, Xu Z. A construct with fluorescent indicators for conditional expression of miRNA. BMC Biotechnol 2008; 8: 77.
53. Belloc F, Dumain P, Boisseau MR, Jalloustre C, Reiffers J, Bernard P et al. A flow cytometric method using Hoechst 33342 and propidium iodide for simultaneous cell cycle analysis and apoptosis determination in unfixed cells. Cytometry 1994; 17: 59-65.
54. Krutzik PO, Clutter MR, Trejo A, Nolan GP. Fluorescent cell barcoding for multiplex flow cytometry. Curr Protoc Cytom 2011; Chapter 6, Unit 6.31.
55. Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP. Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods 2007; 3: 12.